About ViaMune

About company

ViaMune offers a fully synthetic vaccine platform that generates robust immune responses to tumor-specific targets. ViaMune's patented technology provides a unique path to targeting structures found only on tumor cells. ViaMune is seeking financing to complete IND submission, achieve Phase 1 milestones and advance its pipeline. ViaMune is anchored by a leadership team with deep experience in oncology and pharmaceutical development.